Nanox Imaging Ltd. (NASDAQ: NNOX) has entered into a distribution agreement with Costa Rica-based medical equipment distributor SOLME RC, S.A. to market and support the Nanox.ARC, a multi-source digital tomosynthesis system designed to expand access to 3D medical imaging. The agreement, announced in a recent press release, positions Nanox to penetrate a new market and further its vision of making advanced medical imaging more accessible worldwide.
Under the agreement, SOLME will oversee marketing, distribution, installation, training, and ongoing technical support for the Nanox.ARC in Costa Rica. SOLME is a registered supplier to the Caja Costarricense de Seguro Social (CCSS), the country's principal purchaser and provider of hospital services. This relationship could facilitate adoption of the Nanox.ARC within Costa Rica's public healthcare system, potentially accelerating the technology's integration into routine care.
Commercialization will follow applicable regulatory registration, including an initial six-month proof-of-concept device registration period before full registration. This stepwise approach allows for evaluation of the system's performance and compatibility with local clinical needs before broader deployment. The agreement represents Nanox's third Latin American market this year, following entries into Argentina and Peru. This expansion underscores the company's strategic focus on regions where access to advanced imaging may be limited, and where affordable, scalable solutions can address unmet needs.
The Nanox.ARC is a cost-effective, 3D multi-source digital tomosynthesis imaging system designed for ease of use and scalability. It is part of the broader Nanox ecosystem, which combines affordable imaging hardware, advanced AI-based solutions, cloud-based software, access to remote radiology, health IT solutions, and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to care.
Nanox aims to drive the world's transition to preventive health care by delivering an integrated, end-to-end medical imaging and healthcare services platform. The company's vision is to expand the reach of medical imaging both within and beyond traditional hospital settings by providing a seamless solution from scan to interpretation and beyond. By leveraging proprietary digital X-ray technology, AI-driven analytics, and a clinically driven approach, Nanox seeks to enhance the efficiency of routine imaging workflows, support early detection of disease, and improve patient outcomes.
The Nanox ecosystem includes Nanox.ARC; Nanox.AI, a suite of AI-based algorithms that augment the interpretation of routine CT imaging to identify early signs often associated with chronic disease; Nanox.CLOUD, a cloud-based platform for secure data management, storage, and advanced imaging analytics; Nanox.MARKETPLACE and USARAD Holdings, which provide access to remote radiology and cardiology experts and comprehensive teleradiology services; and Nanox Health IT, which combines deep healthcare IT expertise with leading technology partners to deliver RIS, PACS, AI, dictation, and secure infrastructure solutions that streamline workflows and support safer, more efficient care delivery.
This distribution agreement is significant because it represents another step in Nanox's global commercialization strategy. By partnering with a established local distributor like SOLME, Nanox can navigate regulatory hurdles and build trust with healthcare providers. The move also highlights the growing demand for cost-effective imaging solutions in emerging markets, where traditional systems may be too expensive or complex to deploy widely. If successful, the Costa Rica deployment could serve as a model for other countries in the region and beyond, potentially accelerating Nanox's growth and impact.
For investors, the announcement signals progress in Nanox's efforts to monetize its technology and expand its footprint. The company's ability to secure distribution agreements in multiple Latin American markets within a single year demonstrates execution capability and market validation. However, commercialization timelines and regulatory approvals remain key factors to watch. The initial proof-of-concept period will be critical for demonstrating the system's value in a real-world setting.
To view the full press release, visit https://ibn.fm/C77lJ. The latest news and updates relating to NNOX are available in the company's newsroom at http://ibn.fm/NNOX.
